Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.

Clinical pharmacology and therapeutics - 1 Oct 2009

Filipski K K, Mathijssen R H, Mikkelsen T S, Schinkel A H, Sparreboom A

Abstract excerpt

Cisplatin is one of the most widely used anticancer agents for the treatment of solid tumors. The clinical use of cisplatin is associated with dose-limiting nephrotoxicity, which occurs in one-third of patients despite intensive prophylactic measures. Organic cation transporter 2 (OCT2) has been implicated in the cellular uptake of cisplatin, but its role in cisplatin-induced nephrotoxicity remains unknown. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cisplatin
Share to Kidney Diseases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mice, Knockout

Share to Organic Cation Transport Proteins

Share to Organic Cation Transporter 1

Share to Organic Cation Transporter 2

Share to Polymerase Chain Reaction

Source

Open in PubMed Open full text

Identifiers

PMID: 19625999
DOI: 10.1038/clpt.2009.139
PMCID: PMC2746866

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.PMID 19625999Read ↗

Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients.Semantic proximity Read ↗

Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.Semantic proximity Read ↗

Interaction of Cisplatin with the human organic cation transporter 2.Semantic proximity Read ↗

The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug DispositionSemantic proximity Read ↗

Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants.Semantic proximity Read ↗

Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity.Semantic proximity Read ↗

Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving CisplatinSemantic proximity Read ↗

Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney.Semantic proximity Read ↗

Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.Semantic proximity Read ↗

The human organic cation transporter OCT1 and its role as a target for drug responsesSemantic proximity Read ↗

Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity.Semantic proximity Read ↗

Organic cation transporters.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.